3DP Dosage Forms and the Future of Drug Lifecycle Management

Pharmaceutical companies and their drugs face numerous challenges in the brief window between launch and patent expiration. This makes it extremely important to plan lifecycle management (LCM) strategies well in advance of patent expiry. One way to address this is with advanced manufacturing techniques that make it much more difficult for competitors to genericize. For pharmaceutical companies that seek market enhancement strategies beyond the capabilities of existing fast melt technologies, join Contract Pharma for this webinar as we hear from Don Wetherhold, the senior executive advisor and senior vice president of Aprecia Pharmaceuticals. He will talk about the company’s innovative ZipDose technology and why it offers an exclusive opportunity to address patient demand and create products not easily genericized.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Drug Testing in Hair — Applications and the Experience in Brazil

technologynetworks

This webinar will discuss the technology of hair testing and present on the situation in Brazil. There is consequently, a very large numbers of hair tests taking place, and laboratories must meet the need for high throughput and sensitivity.
Watch Now

Safety Evaluation on Extractables and Leachable

In order to ensure the safety of patients, the toxicological risk assessment needs to thoroughly evaluate all potential risks which may be caused by any component present in a pharmaceutical drug product.
Watch Now

From mg to kg: first steps towards a scalable process for drug substances

on24

In this webinar, Anders Högdin, Senior Sales Director at Recipharm discusses the common challenges companies encounter during upscaling. He also outlines the key considerations during the medicinal and process chemistry planning phases, the regulatory requirements and the steps companies can take to streamline the process.
Watch Now

Characterization of Residual Impurities in Gene Therapy Drug Products

Characterization of residual impurities for gene therapy drug products is particularly challenging due to the complex nature of the final products as well as the complicated processes required to manufacture them.
Watch Now